IPO Details

Bidding Dates

03 Aug '23 - 07 Aug '23

Minimum Investment

₹14,820 / 1 Lots (20 Shares)

Price Range

₹705 - ₹741

Maximum Investment

₹192,660 / 13 Lots (260 Shares)

Retail Discount

Not Applicable

Issue Size

₹1,551 Cr

Investor category and sub category

Qualified Institutional Buyers  |   Non-Institutional Investors  |   Retail Individual Investors  |   Employees  |  

Concord Biotech IPO Dates

Important dates with respect to IPO allotment and listing

IPO Opening Date

Aug 3, 2023

IPO Closing Date

Aug 7, 2023

Basis of Allotment

Aug 10, 2023

Initiation of Refunds

Aug 13, 2023

Credit of Shares to Demat Account

Aug 16, 2023

IPO Listing Date

Aug 17, 2023

UPI Mandatory Expiry Date

Aug 7, 2023

Concord Biotech IPO Subscription Details

DateQIBNIIRetailEMPTotal

Day 1Aug 3, 2023

 0.00 0.35 0.38 3.80 0.27

Concord Biotech IPO Subscription Live Status

Investor Category Subscription (Times)
Qualified Institutions Buyers 0.00
Non-Institutional Buyers 0.35
Retail Investors 0.38
Employees 3.80
Total 0.27

About Concord Biotech Ltd

Concord Biopharma started its operations in 2016 and is a leading Indian pharma company engaged in manufacturing selected fermentation-based APIs (Active Pharmaceutical Ingredients) for immunosuppressants and oncology drugs. Concord Biopharma exports to more than 70 countries in the USA, Europe, Japan, Nepal, Mexico, Indonesia, Thailand, Ecuador, Kenya, Singapore, Paraguay, and India. It has established a successful, backwards-integrated, scalable business model. The company is one of the few companies to produce six fermentation-based immunosuppressant APIs.

Concord Biotech is expanding to include anti-fungal and oncology drug APIs. 

Concord Biotech Ltd IPO Details

Concord Biotech is a 100% offer for sale worth ₹1,551.00 crore. The issue comprises 20,925,652 shares and is priced at ₹705 to ₹741 per share. Retail investors can bid for the Concord Biotech Limited IPO, which will open on August 4, 2023. Concord Biotech Limited’s IPO will list on the BSE and NSE exchanges on August 18, 2023.

Concord Biotech Ltd IPO Objective 

  1. To achieve the benefits of listing on the stock exchanges
  2. To carry out the offer for sale of up to 20,925,652 shares

Noteworthy Highlights Of Concord Biotech Ltd

  • As of March 31, 2022, the annual installed capacity for formulation manufacturing was 522.64 million units.
  • The company caters to 200 customers in 70 countries and offers a diversified product portfolio of 27 brands across immunosuppressant API, nephrology, anti-fungal, anti-infective, oncology, and critical care drugs APIs. 

Competitive Peers 

Other listed players in the segment recognised by Concord Biotech Ltd are Divi’s Laboratories, Suven Pharmaceuticals, Laurus Labs, and Shilpa Medicare. 

Concord Biotech Ltd Company Financials

Particulars March 31, 2023 (₹ in million) March 31, 2022 (₹ in million) March 31, 2021 (₹ in million)
Total Income 8,884.77 7,363.49 6,307.50
Profit After Tax (PAT) 2,400.84 1,749.29 2,348.87
Net Worth 12,900.01 11,032.23 9,993.73
Earnings Per Share 22.95 16.72 22.45
Total Borrowings 312.36 605.86 863.49

Know before investing

Strengths

2

  1. The net worth of the company increased from ₹9,993.73 million on March 31, 2021, to ₹12,900.01 million on March 31, 2023.

  2. Concord Biopharma is a leader in its segment with a 20% market share in 2022, in terms of volume.

Risks

2

  1. Concord Biotech’s revenue is dependent on limited customers and any interruption in the client’s demand can adversely impact the company’s revenue.

  2. If the company is not able to obtain trademarks and patents for their products, the business can get impacted.

  • How to Apply in IPO
  • How to Check IPO Allotment Status
Play Button

Login to Angel One App / Website & click on IPO

Select desired IPO & tap on "Apply"

Enter UPI ID, set quantity/price & submit

Accept mandate on the UPI app to complete the process

Play Button

Login to Angel One App / Website

Choose IPO section on Home Page

Click IPO Orders

Chose the IPO application you want to view the status for

Concord Biotech Ltd IPO FAQs

What is Concord Biotech Limited's IPO?

The Concord Biotech Ltd IPO is 100% Offer for Sale IPO worth ₹1,551 crore. The issue comprises 20,925,652 shares and is priced at ₹705 to ₹741 per share. The IPO will open on August 4, 2023.  

When will Concord Biotech Limited's IPO be allotted?

The Basis of Allotment will happen on Friday, August 11, 2023.

When will Concord Biotech Limited's IPO open for subscription?

The IPO subscription window will open on Friday, August 04, 2023.

What minimum lot size can retail investors subscribe to?

Retail investors can apply for a minimum of one lot, which consists of 20 shares.

When will Concord Biotech Limited list on exchanges?

Concord Biotech Ltd IPO will list on the BSE and NSE exchanges on  Friday, August 18, 2023.

How do I check the allotment status of the Concord Biotech Limited IPO?

Steps to check IPO allotment status on Angel One’s app:

  • Log in to the Angel One app
  • Validate with an OTP
  • Enter your application number, DP ID, and PAN number into the app
  • Click on ‘Submit’

What would be the listing gains on the Concord Biotech Limited IPO?

Listing gains cannot be ascertained before the listing of the IPO on the stock exchange, which is  Friday, August 18, 2023, for Concord Biotech Ltd. 

I have finished the application process for the Concord Biotech Limited IPO, but the funds still need to be debited. What is the reason?

The bank will only block the amount initially in your account. Under the new system, the money isn’t debited until the stocks are allotted to you. 

How do I approve the UPI mandate request for Concord Biotech Limited's IPO?

You must complete the payment process by logging in to your UPI handle and approving the payment mandate.

Can I submit more than one application for the public issue of Concord Biotech Limited using one PAN?

You can submit only one application using your PAN card.